Swiss National Bank Has $68.92 Million Position in Illumina, Inc. (NASDAQ:ILMN)

Swiss National Bank cut its position in shares of Illumina, Inc. (NASDAQ:ILMN) by 2.7% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 495,000 shares of the life sciences company’s stock after selling 13,500 shares during the quarter. Swiss National Bank’s holdings in Illumina were worth $68,924,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of ILMN. Annis Gardner Whiting Capital Advisors LLC acquired a new stake in shares of Illumina in the third quarter valued at approximately $30,000. VisionPoint Advisory Group LLC increased its stake in Illumina by 344.6% in the 3rd quarter. VisionPoint Advisory Group LLC now owns 249 shares of the life sciences company’s stock valued at $34,000 after buying an additional 193 shares during the last quarter. Wetzel Investment Advisors Inc. acquired a new stake in Illumina in the 4th quarter valued at $37,000. Gradient Investments LLC lifted its position in Illumina by 375.0% during the 4th quarter. Gradient Investments LLC now owns 285 shares of the life sciences company’s stock worth $40,000 after buying an additional 225 shares in the last quarter. Finally, North Star Investment Management Corp. boosted its stake in shares of Illumina by 183.0% during the 4th quarter. North Star Investment Management Corp. now owns 300 shares of the life sciences company’s stock worth $42,000 after buying an additional 194 shares during the last quarter. Institutional investors and hedge funds own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on ILMN shares. HSBC downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, January 16th. Stephens reiterated an “overweight” rating and set a $170.00 price objective on shares of Illumina in a research note on Wednesday, April 10th. Royal Bank of Canada reissued an “outperform” rating and issued a $253.00 target price on shares of Illumina in a research note on Tuesday, April 9th. Barclays upped their price target on shares of Illumina from $85.00 to $100.00 and gave the stock an “underweight” rating in a research report on Wednesday, April 10th. Finally, OTR Global reiterated a “mixed” rating on shares of Illumina in a research note on Wednesday, March 20th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and eight have issued a buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $165.10.

Insider Activity

In related news, CEO Jacob Thaysen purchased 7,330 shares of Illumina stock in a transaction that occurred on Thursday, February 22nd. The shares were acquired at an average price of $135.29 per share, with a total value of $991,675.70. Following the completion of the transaction, the chief executive officer now directly owns 14,861 shares of the company’s stock, valued at approximately $2,010,544.69. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.17% of the stock is owned by company insiders.

Illumina Stock Performance

ILMN stock opened at $117.93 on Monday. The business’s fifty day moving average price is $130.03 and its two-hundred day moving average price is $127.00. Illumina, Inc. has a fifty-two week low of $89.00 and a fifty-two week high of $213.91. The company has a current ratio of 1.75, a quick ratio of 1.36 and a debt-to-equity ratio of 0.26.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, May 2nd. The life sciences company reported $0.09 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.05. The business had revenue of $1.08 billion for the quarter, compared to analyst estimates of $1.05 billion. Illumina had a negative net margin of 28.71% and a positive return on equity of 2.31%. Illumina’s revenue for the quarter was down 1.0% compared to the same quarter last year. During the same period last year, the firm earned $0.08 earnings per share. As a group, analysts anticipate that Illumina, Inc. will post 0.91 EPS for the current year.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.